Stevanato Group(US:STVN) ZACKS·2026-03-04 13:46分组1 - Stevanato Group reported quarterly earnings of $0.21 per share, exceeding the Zacks Consensus Estimate of $0.20 per share, and showing an earnings surprise of +6.06% [1] - The company achieved revenues of $403.37 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.96%, compared to $352.68 million in the same quarter last year [2] - Stevanato has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed, losing about 26.8% since the beginning of the year, while the S&P 500 has only declined by 0.4% [3] - The current consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $311.54 million, and for the current fiscal year, it is $0.73 on revenues of $1.48 billion [7] - The Medical - Drugs industry, to which Stevanato belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]